Europe Colorectal Cancer Market Analysis and Opportunities by 2027
Historic Data: 2017-2018 | Base Year: 2019 | Forecast Period: 2020-2027Europe Colorectal Cancer Market to 2027 - Regional Analysis and Forecasts by Modality (Diagnosis Type, Therapy Type, Imaging Type); End User (Hospitals, Diagnostic and Research Laboratories), and Country
- Report Date : Feb 2020
- Report Code : TIPRE00009258
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 229
Europe, the colorectal cancer market, is anticipated to reach US$ 5,573.2 Mn in 2027 from US$ 4,241.2 Mn in 2019. The market is projected to grow with a CAGR of 3.5% from 2020-2027.
The rise of the colorectal cancer market is driven by factors such as the increasing prevalence of colorectal cancer, and benefits offered by generic drugs that are boosting the market over the years. But, pricing pressure on drug manufacturers is likely to hinder the growth of the market in the future years.
Generic drugs are alternatives of branded drugs. The pharmacological effects of generic drugs are similar to their branded counterparts. Generic drugs are cost-effective as the manufacturers does not invest in the development and marketing a new drug. After the expiry of a drug patent, other manufacturers apply for FDA approval of a generic intended for its manufacturing and selling. Thus, the generic drugs are cheaper than their branded counterparts. The generic drug have exactly the same dosage, effects, side effects, route of administration, risks, safety, and strength as that of the original branded drugs. Generic drugs are important in oncology due to the fact that some of the anticancer drugs are only offered as generics. Patients are likely seen to abandon branded prescriptions which are majorly associated with their higher co-pays. Among developing countries such as India, where the paying capacity is relatively low, generic drugs for cancer treatment acts as a boon for both the manufacturers as well as patients due to its affordability and efficacy. For instance, in June 2016, Hetero launched a Biosimilar 'Bevacizumab' for the treatment of metastatic colorectal cancer under the brand name “Cizumab”. One of the most striking benefit of using generic drugs is the cost that is up to 85% less than that of the branded drugs.
In 2019, the Germany accounted for the largest market share in Europe colorectal cancer market, and it is also expected to grow at a faster pace over the forecast period. The market for colorectal cancer in the country is expected to grow due to the rising development in the field of cancer. Across the country, there are various biopharmaceutical and pharmaceutical companies. Various multinational companies are conducting market consolidation strategies to expand the oncology segment. Hence, considering the mentioned factors, the colorectal cancer market is expected to grow at a significant pace in the US during the forecast period.
Germany Colorectal Cancer Market Revenue and Forecasts to 2027 (US$ Mn)
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
EUROPE COLORECTAL CANCER – MARKET SEGMENTATION
By Modality
- Diagnosis Type
- Immunohistochemistry
- Stool Test
- Flexible Sigmoidoscopy
- Colonoscopy
- CEA Test
- Others
- Therapy Type
- Chemotherapy
- Alkylating Agent
- Antimetabolites
- Others
- Immunotherapy
- Panitumumab
- Cetuximab
- Bevacizumab
- Others
- Chemoprotectant
- Others
- Imaging Type
- Computed Tomography (CT)
- Magnetic Resonance Imaging (MRI)
- Others
By End User
- Hospitals
- Diagnostic and Research Laboratories
By Geography
Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
Company Profiles
- Epigenomics AG
- Novigenix SA
- Clinical Genomics Technologies Pty Ltd.
- EDP Biotech Corporation
- Volitionrx Limited
- Abbott Laboratories
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Bruker Corporation
- Quest Diagnostics Incorporated
- Natera, Inc.
- Guardant Health, Inc.
Europe Colorectal Cancer Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2019 | US$ 4,241.2 Million |
| Market Size by 2027 | US$ 5,573.2 Million |
| Global CAGR (2020 - 2027) | 3.5% |
| Historical Data | 2017-2018 |
| Forecast period | 2020-2027 |
| Segments Covered |
By Modality
|
| Regions and Countries Covered | Europe
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
The List of Companies - Europe Colorectal Cancer Market
- Epigenomics AG
- Novigenix SA
- Clinical Genomics Technologies Pty Ltd.
- EDP Biotech Corporation
- Volitionrx Limited
- Abbott Laboratories
- Amgen Inc.
- F. Hoffmann-La Roche AG
- Bruker Corporation
- Quest Diagnostics Incorporated
- Natera, Inc.
- Guardant Health, Inc.
Get Free Sample For